Neurocrine Biosciences enters obesity race with novel CRF2 peptide agonist

Neurocrine Biosciences (NASDAQ:NBIX) officially entered the clinical arena for metabolic disorders today, announcing the initiation of a Phase 1 first-in-human study for NBIP-'2118.

The candidate is a Corticotropin-Releasing Factor Receptor 2 (CRF2) peptide agonist being developed as a potential best-in-class treatment for obesity and weight management.

The Phase 1 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of NBIP-'2118.

The study will enroll a diverse cohort of healthy-weight, overweight, and obese adults.

Neurocrine expects to report initial data from this trial in 2027.

While current GLP-1 agonists have set a high bar for weight loss, a significant concern remains the loss of lean muscle mass alongside adipose tissue.

NBIP-'2118 aims to address this gap.

Preclinical data showcased a unique profile: significant fat loss coupled with the preservation or even an increase in lean mass.

Designed for once-weekly subcutaneous administration, the peptide targets the CRF2 receptor, which plays a critical role in metabolic regulation and energy expenditure.

By focusing on body composition rather than just total weight reduction, Neurocrine is positioning NBIP-'2118 as a sophisticated alternative or adjunct to existing therapies.

The initiation of the NBIP-'2118 study marks a strategic expansion for Neurocrine, which is rapidly building a comprehensive metabolic portfolio to complement its established neurology and endocrinology franchises.